Collector
Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion | Collector
Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion
Quartz

Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion

The deal targets KRAS-driven tumors, which J&J says have limited treatment options and survival measured in months

Go to News Site